{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:56Z","timestamp":1792787276758,"version":"4.5.0"},"reference-count":40,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009128","name":"Research for Patient Benefit Programme","doi-asserted-by":"publisher","award":["PB-PG-0614-34090"],"award-info":[{"award-number":["PB-PG-0614-34090"]}],"id":[{"id":"10.13039\/501100009128","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Orphan Biovitrum AB","award":["000"],"award-info":[{"award-number":["000"]}],"id":[{"id":"https:\/\/ror.org\/04asvbz37","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,8,24]]},"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1136\/bmjopen-2025-114454","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:35:30Z","timestamp":1790775330000},"page":"e114454","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Anakinra versus intramuscular methylprednisolone acetate for gout flares in people with chronic kidney disease (ASGARD): a UK randomised multicentre, double-blind, double-dummy controlled feasibility study with economic, qualitative and safety assessment"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct02578394","registry":"10.18810\/clinical-trials-gov","type":"postResults"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4935-7233","authenticated-orcid":false,"given":"Gowrie","family":"Balasubramaniam","sequence":"first","affiliation":[{"name":"Department of Renal Medicine, Mid and South Essex NHS Foundation Trust, Basildon, UK"},{"name":"Anglia Ruskin University, Chelmsford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Almond","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Anglia Ruskin University, Chelmsford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Harnett","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Medical Specialist Group LLP, Saint Martin, Guernsey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Turner","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, University of East Anglia Norwich Medical School, Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Scales","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, University of Essex, Colchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-6212","authenticated-orcid":false,"given":"Jufen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Anglia Ruskin University, Chelmsford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Moore","sequence":"additional","affiliation":[{"name":"Anglia Ruskin University, Chelmsford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4223-0659","authenticated-orcid":false,"given":"Karen","family":"Hayden","sequence":"additional","affiliation":[{"name":"Anglia Ruskin University, Chelmsford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Roddy","sequence":"additional","affiliation":[{"name":"Research Institute for Primary Care and Health Sciences, Keele University, Keele, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mallen","sequence":"additional","affiliation":[{"name":"Keele University, Keele, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Stack","sequence":"additional","affiliation":[{"name":"Mater Misericordiae University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Bhagat","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, West Suffolk Hospitals NHS Trust, Bury Saint Edmunds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Ng","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St Thomas\u2019 Hospitals NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rutherford","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5523-6534","authenticated-orcid":false,"given":"Bhaskar","family":"Dasgupta","sequence":"additional","affiliation":[{"name":"Rheumatology, Anglia Ruskin University, Chelmsford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"2026100907200546000_16.9.e114454.1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13075-021-02416-y","article-title":"Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review","volume":"23","author":"Pisaniello","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2026100907200546000_16.9.e114454.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.09.012"},{"key":"2026100907200546000_16.9.e114454.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.03.013"},{"key":"2026100907200546000_16.9.e114454.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0441-1"},{"key":"2026100907200546000_16.9.e114454.5","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0610-9"},{"key":"2026100907200546000_16.9.e114454.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq363"},{"key":"2026100907200546000_16.9.e114454.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.27327"},{"key":"2026100907200546000_16.9.e114454.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216154"},{"key":"2026100907200546000_16.9.e114454.9","first-page":"1325","article-title":"Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis","volume":"21","author":"Siegel","year":"1994","journal-title":"J Rheumatol"},{"key":"2026100907200546000_16.9.e114454.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200908"},{"key":"2026100907200546000_16.9.e114454.11","doi-asserted-by":"publisher","DOI":"10.1186\/ar3297"},{"key":"2026100907200546000_16.9.e114454.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60799-0"},{"key":"2026100907200546000_16.9.e114454.13","unstructured":"Available: https:\/\/bnf.nice.org.uk\/treatment-summaries\/glucocorticoid-therapy\/"},{"key":"2026100907200546000_16.9.e114454.14","doi-asserted-by":"publisher","DOI":"10.1038\/nature04516"},{"key":"2026100907200546000_16.9.e114454.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.27600"},{"key":"2026100907200546000_16.9.e114454.16","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/art.41699","article-title":"A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares","volume":"73","author":"Saag","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026100907200546000_16.9.e114454.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.33412"},{"key":"2026100907200546000_16.9.e114454.18","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/acr.21690","article-title":"Rilonacept (interleukin\u20101 trap) for prevention of gout flares during initiation of uric acid\u2013lowering therapy: Results from a phase III randomized, double\u2010blind, placebo\u2010controlled, confirmatory efficacy study","volume":"64","author":"Schumacher","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026100907200546000_16.9.e114454.19","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/ar4159","article-title":"Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator","volume":"15","author":"Terkeltaub","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2026100907200546000_16.9.e114454.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.144063"},{"key":"2026100907200546000_16.9.e114454.21","doi-asserted-by":"publisher","DOI":"10.1186\/ar2143"},{"key":"2026100907200546000_16.9.e114454.22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jbspin.2018.03.015","article-title":"Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study","volume":"85","author":"Loustau","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2026100907200546000_16.9.e114454.23","doi-asserted-by":"crossref","unstructured":"Janssen CA , Oude Voshaar MAH , Vonkeman HE , et al . Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology (Oxford) 2019. doi:10.1093\/rheumatology\/key402","DOI":"10.1093\/rheumatology\/key402"},{"key":"2026100907200546000_16.9.e114454.24","doi-asserted-by":"crossref","unstructured":"Balasubramaniam G , Parker T , Turner D , et al . Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protocol study. BMJ Open 2017;7. doi:10.1136\/bmjopen-2017-017121","DOI":"10.1136\/bmjopen-2017-017121"},{"key":"2026100907200546000_16.9.e114454.25","unstructured":"Treatment of an Acute Gout Flare in Patients with Kidney Disease: A Questionnaire Survey. Br J Rheumatol 2015;54."},{"key":"2026100907200546000_16.9.e114454.26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131246"},{"key":"2026100907200546000_16.9.e114454.27","doi-asserted-by":"publisher","DOI":"10.1002\/pst.185"},{"key":"2026100907200546000_16.9.e114454.28","first-page":"620","article-title":"The Health Assessment Questionnaire Disability Index is a valid measure of physical function in gout","volume":"26","author":"Taylor","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2026100907200546000_16.9.e114454.29","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131244"},{"key":"2026100907200546000_16.9.e114454.30","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2026100907200546000_16.9.e114454.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.02.008"},{"key":"2026100907200546000_16.9.e114454.32","first-page":"4371","article-title":"The Lower Extremity Functional Scale: Scale development, measurement properties, and clinical application","volume":"79","author":"Binkley","year":"1999","journal-title":"Phys Ther"},{"key":"2026100907200546000_16.9.e114454.33","unstructured":"2019\/20 national cost collection data. NHS England. Available: https:\/\/www.england.nhs.uk\/publication\/2019-20-national-cost-collection-data-publication\/August 2022"},{"key":"2026100907200546000_16.9.e114454.34","unstructured":"Lesley C , Amanda B . Unit costs of health and social care 2020. University of Kent, Canterbury; January 31, 2021. Available: https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2020 [accessed Aug 2022]"},{"key":"2026100907200546000_16.9.e114454.35","unstructured":"Available: https:\/\/bnf.nice.org.uk\/"},{"key":"2026100907200546000_16.9.e114454.36","unstructured":"National Institute for Health and Care Excellence (NICE) . Position statement on use of the eq-5d-5l value set for england (updated october 2019). London, 2019."},{"key":"2026100907200546000_16.9.e114454.37","unstructured":"Available: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/articles\/overviewoftheukpopulation\/january2021"},{"key":"2026100907200546000_16.9.e114454.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204463"},{"key":"2026100907200546000_16.9.e114454.39","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp18X697997"},{"key":"2026100907200546000_16.9.e114454.40","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190257"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-114454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:20:17Z","timestamp":1791555617000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-114454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,30]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2025-114454"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-114454","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}